Neal D. Shore, MD, introduces a real-time high resolution micro-ultrasound system for calculating prostate malignancy risk levels and guiding prostate biopsies. He also compares accuracy and practical benefits of micro-ultrasound to conventional ultrasound and MRI-guided biopsy techniques.
Read More
Kevin T. McVary, MD, illustrates that while nocturia is the leading lower urinary tract symptom (LUTS) complaint that prompts men to seek out urological care, the condition persists without improvement in 50% of patients, even after treatment. Therefore, there is a significant unmet need in nocturia management practices. He discusses the condition’s financial and quality of life (QOL) burdens, its multifactorial etiology, and his perspective on treatment approaches.
Read More
Fred Bartlit, a renowned trial lawyer with 60 years of experience, explains the science behind exercising to combat sarcopenia. During this discussion with E. David Crawford, MD, he summarizes the main points of his book Choosing the StrongPath: Reversing the Downward Spiral of Aging.
Read More E. David Crawford, MD, argues for using PSA levels of 1.5 ng/mL as the cutoff for routine screening in primary care. He emphasizes the importance of informed decision making in the event of abnormal results, reducing unnecessary biopsies and overdiagnosis, and relying more on genomic markers for detecting significant cancers.
Read More Ronald F. Tutrone, Jr., MD, FACS, summarizes two Phase III clinical trials testing the safety and efficacy of fexapotide, a novel treatment for benign prostatic hyperplasia (BPH).
Read More